<p class="first" id="d4700015e255">Available data from observational studies on the
association of admission hyperglycemia
(aHG) with outcomes of patients with acute ischemic stroke (AIS) treated with intravenous
thrombolysis (IVT) are contradictory, especially when stratified by diabetes mellitus
(DM) history. We assessed the association of aHG (≥144 mg/dL) with outcomes stratified
by DM history using propensity score-matched (PSM) data from the SITS-ISTR. The primary
safety outcome was symptomatic intracranial hemorrhage (SICH); 3-month functional
independence (FI) (modified Rankin Scale [mRS] scores 0-2) represented the primary
efficacy outcome. Patients with and without aHG did not differ in baseline characteristics
both in the non-DM (n = 12,318) and DM (n = 6,572) PSM subgroups. In the non-DM group,
patients with aHG had lower 3-month FI rates (53.3% vs. 57.9%, P < 0.001), higher
3-month mortality rates (19.2% vs. 16.0%, P < 0.001), and similar symptomatic intracerebral
hemorrhage (SICH) rates (1.7% vs. 1.8%, P = 0.563) compared with patients without
aHG. Similarly, in the DM group, patients with aHG had lower rates of 3-month favorable
functional outcome (mRS scores 0-1, 34.1% vs. 39.3%, P < 0.001) and FI (48.2% vs.
52.5%, P < 0.001), higher 3-month mortality rates (23.7% vs. 19.9%, P < 0.001),
and
similar SICH rates (2.2% vs. 2.7%, P = 0.224) compared with patients without aHG.
In conclusion, aHG was associated with unfavorable 3-month clinical outcomes in patients
with and without DM and AIS treated with IVT.
</p>